Therapeutic efficacy of three-dimensional conformal radiation therapy for patients with locally advanced non-small cell lung cancer.
- Author:
Jian-zhong CAO
1
;
Guang-fei OU
;
Jun LIANG
;
Ji-ma LÜ
;
Zong-mei ZHOU
;
Dong-fu CHEN
;
Ze-fen XIAO
;
Qin-fu FENG
;
Hong-xing ZHANG
;
Lü-hua WANG
;
Wei-bo YIN
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Carcinoma, Non-Small-Cell Lung; drug therapy; pathology; radiotherapy; Chemoradiotherapy; Female; Follow-Up Studies; Hemoglobins; metabolism; Humans; Lung Neoplasms; drug therapy; pathology; radiotherapy; Male; Neoplasm Staging; Radiation Pneumonitis; etiology; Radiotherapy Dosage; Radiotherapy, Conformal; adverse effects; methods; Survival Rate
- From: Chinese Journal of Oncology 2011;33(7):529-534
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the treatment results of three-dimensional conformal radiotherapy (3D-CRT) and conventional radiotherapy (2D) for patients with locally advanced non-small-cell lung cancer (NSCLC).
METHODSFive hundred and twenty seven patients with stage III NSCLC treated between Jan 2000 and Dec 2006 were included in this study. Among them, 253 cases were treated with 3D-CRT, and 274 with conventional radiotherapy. In the 3D group, 159 (62.8%) patients received chemoradiotherapy, 77 with total radiotherapy dose of > 60 Gy, 49 with 50 - 60 Gy. In the 2D group, 127 (46.4%) patients received chemoradiotherapy, 48 with total radiotherapy dose of > 60 Gy, 75 with 50 - 60 Gy.
RESULTSThe 1-, 3-, 5-year overall survival rates (OS) and median survival time for patients treated with 3D-CRT were 73.3%, 26.1%, 14.4% and 20.1 months, respectively, and that of patients treated with 2D radiotherapy were 61.0%, 13.8%, 8.0% and 15.6 months, respectively (P = 0.002). The 1-, 3-, 5-year cause-specific survival rates (CSS) were 79.0%, 33.3%, and 20.8% for the 3D group and 65.1%, 16.7%, 11.2%, respectively, for the 2D group (P = 0.000). The 1-, 3-, and 5-year locoregional control rates were 71.6%, 34.3% and 31.0% for patients treated with 3D radiotherapy and 57.3%, 22.1% and 19.2%, respectively, for patients treated with 2D treatment (P = 0.002). The results of multivariate analysis showed that 3D-CRT, KPS, clinical tumor response and pretreatment hemoglobin level were independently associated with increased OS and CSS. No statistically significant differences were found between the radiation complications in the two groups.
CONCLUSIONSThe results of our study demonstrate that 3D-conformal radiotherapy improves the survival rate in patients with stage III NSCLC compared with that of 2D radiation therapy.